Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Very long-chain polyunsaturated fatty acids (VLC-PUFAs) are a specialized class of lipids with carbon chains exceeding 24 atoms (typically C26-C38) and multiple double bonds, synthesized primarily by the enzyme ELOVL4 (Agbaga et al., 2008, PNAS). These lipids are essential structural components of membranes in high-activity tissues such as the retina, brain, and testes, where they maintain the fluidity and integrity of specialized microdomains like photoreceptor outer segments (Harker et al., 2014, Journal of Lipid Research). Beyond their structural role, VLC-PUFAs serve as precursors to elovanoids, which are potent bioactive signaling molecules that protect cells against oxidative stress and apoptosis (Bhattacharjee et al., 2017, Science Advances). Mutations in the biosynthetic pathway of VLC-PUFAs are linked to severe pathologies, including Stargardt disease 3 (STGD3), spinocerebellar ataxia type 34 (SCA34), and certain forms of ichthyosis (Ozaki et al., 2015, JAMA Ophthalmology). While VLC-PUFAs are not traditional protein targets for drug inhibition, they are the focus of therapeutic strategies aimed at lipid replacement or the use of synthetic elovanoid derivatives to treat neurodegenerative and retinal disorders (Jun et al., 2017, Scientific Reports).
Metabolic precursors for the synthesis of neuroprotective elovanoids and structural components of specialized membrane microdomains.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Very long-chain polyunsaturated fatty acid (VLC-PUFA).